Heron Therapeutics | HRTX - Pasivo Circulante





Pasivo Circulante Cambio Fecha
ALKERMES USD 651.93M 10.16M 2026-09
Alnylam Pharmaceuticals USD 2.06B 550.49M 2026-09
Amarin USD 175.14M 10.94M 2026-09
ANI Pharmaceuticals USD 283.65M 44.14M 2026-06
Anika Therapeutics USD 22.15M 1.18M 2026-06
Arrowhead Research USD 283.35M 11.87M 2026-06
Eisai JPY 393.64B 53.39B 2026-06
Emergent BioSolutions USD 651.3M 12.7M 2023-12
GlaxoSmithKline GBP 20.72B 814M 2026-09
Heron Therapeutics USD 92.14M 1.63M 2026-06
Insmed USD 596.57M 157.83M 2026-09
Ligand Pharmaceuticals USD 500.57M 453.83M 2026-09
Merck USD 28.8B 1.07B 2026-09
Nektar Therapeutics USD 57.71M 4.17M 2026-03
Neurocrine Biosciences USD 984.6M 110.1M 2026-09
Omeros USD 85.5M 2.28M 2025-06
Pacira USD 122.01M 13.22M 2026-06
Regeneron Pharmaceuticals USD 6.2B 671.5M 2026-09
Roche Holding CHF 28.85B 846M 2026-06
Sangamo BioSciences USD 47.66M 1.9M 2025-06
Ultragenyx Pharmaceutical USD 389M 38M 2026-09
Veracyte USD 62.74M 6.62M 2026-06
Vertex Pharmaceuticals USD 5B 1.06B 2026-09